UK Insomnia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
UK · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$83.3 MnPlaceholder estimate
Estimate 2025$86.2 Mn2.6% of the global market
Projected 2034$116.4 Mn 35.1%Adds $30.3 Mn over 9 forecast years
CAGR 2025–20343.4%Faster than 18% of 180 Pharmaceuticals markets here
11 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The UK Insomnia Treatment Market Analysis Executive Summary
Insomnia treatment helps people fall and stay asleep with newer medicines, digital CBT for insomnia and sleep aids.
Key segments of the insomnia Treatment market include treatment (Orexin Receptor Antagonists, Z-Drugs and Melatonin Agonists) and type (Short-Term Insomnia and Chronic Insomnia).
UK Insomnia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
UK Insomnia Treatment Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the insomnia Treatment market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the insomnia Treatment market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the insomnia Treatment market.
Competitive Landscape for Insomnia Treatment Market in UK
The insomnia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Insomnia Treatment Market in UK
Insomnia Treatment in the UK: rules, payment and research
The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK.[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.[2] ClinicalTrials.gov lists 11 studies on Insomnia Treatment that are recruiting, active or about to start in the UK.[3] Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure for the UK.[4]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insomnia Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Idorsia
7.2 Merck & Co.
7.3 Eisai
7.4 Sanofi
7.5 Big Health
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The insomnia Treatment market can be segmented based on various criteria, including treatment, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Insomnia Treatment right now, from free public sources.
How big is the Insomnia Treatment market in the UK?
Placeholder estimate: about $86.2 Mn in 2025, rising to about $116.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Insomnia Treatment market in the UK growing?
Placeholder estimate: about 3.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Insomnia Treatment market report cover?
The report splits the market by treatment (Orexin Receptor Antagonists, Z-Drugs, Melatonin Agonists, Digital CBT-I), type (Short-Term Insomnia, Chronic Insomnia) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Insomnia Treatment market?
Key players include Idorsia, Merck & Co., Inc., Eisai Co., Sanofi and Big Health.
What is driving the Insomnia Treatment market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the insomnia Treatment market. Governments and employers are investing more in mental health care.
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Insomnia Treatment are running in the UK?
11 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
What does WHO report for the UK?
Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the UK are 65 or older?
19.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
UK 
Germany
Russia
US
China
Canada
Japan
Italy
Brazil
France
Ecuador
India
Saudi Arabia
Spain
Mexico
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
Aurobindo Pharma
Teva Pharmaceutical
Hikma Pharmaceuticals PLC
ResMed Inc.